Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter G. Schultz
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter G. Schultz

Peter G. Schultz

Co-Founder, Ardelyx

Crunchbase

Peter G. Schultz's Career

Ardelyx
Ardelyx

Fremont, CA, US

Co-Founder
Biovia
Biovia

San Diego, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter G. Schultz's Career

Ardelyx
Ardelyx
Public$471.4M1332007Fremont, CA, US
Co-Founder

Leadership at Ardelyx

Jan LundbergJan LundbergBoard Member
Rick RodgersRick RodgersBoard Member
Michael RaabMichael RaabBoard Member
Dominique CharmotDominique CharmotCo-Founder
Geoffrey A. BlockGeoffrey A. BlockBoard Member
Onaiza Cadoret-ManierOnaiza Cadoret-ManierBoard Member

Similar to Ardelyx

Elcelyx TherapeuticsElcelyx TherapeuticsSan Diego, CA, USPharmaceuticalsest. 2010Elcelyx TherapeuticsSan Diego, CA, US · est. 2010

Elcelyx Therapeutics develops nutrient-based solutions for weight management and metabolic disorders.

Series E · $96.8M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Biovia
Biovia
Acquired02001San Diego, CA, US
Co-Founder

Leadership at Biovia

Alejandro ZaffaroniAlejandro ZaffaroniCo-Founder
Jason BenedictJason BenedictCEO
Ricardo LevyRicardo LevyBoard Member
Ken ColemanKen ColemanBoard Member
Larry R FergusonLarry R FergusonBoard Member

Similar to Biovia

SchrödingerSchrödingerNew York City, NY, USDrug Discovery, Softwareest. 1990SchrödingerNew York City, NY, US · est. 1990

Schrödinger, Inc.: A global life sciences firm specializing in drug discovery software.

Public · $567.2M787
Insightful ScienceInsightful ScienceSan Diego, CA, USBioinformatics, Softwareest. 2017Insightful ScienceSan Diego, CA, US · est. 2017

Insightful Science: A global full-stack software solutions provider for over 2M scientists.

Late Stage Private · $95M750

Peter G. Schultz's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Peter G. Schultz

Colin PovallColin PovallCo-Founder · Applied BiosciencesGrace ZhaoGrace ZhaoCo-Founder · AccuraGenScott StevensScott StevensCo-Founder · Applied BiosciencesGerard MalangaGerard MalangaCo-Founder · DataBiologicsDeborah ZanforlinDeborah ZanforlinCo-Founder · ConquerXPaul Schulze-LefertPaul Schulze-LefertCo-Founder · AgBiome